Baseline and demographics |
|
Age (years), mean (range) |
59 (20‐80) |
Sex |
7 females |
20 males |
BMI, mean (range) |
27.3 (21.5‐37.7) |
Comorbidities |
|
Obesity (%) |
7 (25.9) |
DM (%) |
6 (22.2) |
Symptoms and hospital course |
|
O2 saturation at admission |
94 (69‐100) |
Supplemental O2 (%) |
27 (100) |
Invasive mechanical ventilation |
23 (85.2) |
Previous medications received |
|
ACE inhibitor |
6 (22.2) |
Captopril |
5 (18.5) |
Enalopril/hydrochlorothiazide |
1 (3.7) |
Antiarrhythmic |
|
Amiodarone |
1 (3.7) |
Antibiotics |
|
Amoxicillin |
2 (7.4) |
Azithromycin |
15 (55.5) |
Ceftriaxone |
20 (74.1) |
Cephalexin |
1 (3.7) |
Cephepime |
1 (3.7) |
Clarithromycin |
6 (22.2) |
Clindamycin |
1 (3.7) |
Piperacillin/tazobactam |
1 (3.7) |
Vancomycin |
1 (3.7) |
Antiretrovirals |
0 (0) |
Immunobiologics |
0 (0) |
Bronchodilators (fenoterol, ipratropium, aminophylline) |
1 (3.7) |
Ibuprofen |
1 (3.7) |
Statin (simvastatin) |
1 (3.7) |
Steroids (hydrocortisone) |
1 (3.7) |
Medications received during day 1 |
|
ACE inhibitor (captopril) |
2 (7.4) |
Antibiotics |
27 (100) |
Amoxicillin |
0 (0) |
Azithromycin |
22 (81.5) |
Ceftriaxone |
0 (0) |
Cephalexin |
0 (0) |
Cephepime |
0 (0) |
Clarithromycin |
4 (14.8) |
Clindamycin |
1 (3.7) |
Piperacillin/tazobactam |
1 (3.7) |
Vancomycin |
0 (0) |
Anticoagulation |
18 (66.7) |
Enoxaparin |
15 (55.5) |
Heparin |
4 (14.8) |
Antivirals (Tamiflu) |
22 (81.5) |
Bronchodilators |
0 (0) |
Insulin |
3 (11.1) |
Steroids |
4 (14.8) |
Hydrocortisone |
2 (7.4) |
Prednisone |
1 (3.7) |
Methylprednisone |
1 (3.7) |
Vasopressors |
14 (51.8) |
Dobutamine |
0 (0) |
Dopamine |
0 (0) |
Norepinephrine |
14 (51.8) |
Laboratory values, mean (range)/number |
|
AST (units/L) |
92.2 (29.3‐343)/13 |
ALT (IU/L) |
100.61 (22.1‐533.3)/15 |
Total bilirubin (mg/dL) |
1.13 (0.15‐3.08)/14 |
Hemoglobin (g/dL) |
11.0 (6.2‐14.5)/27 |
Platelets (103/μL) |
217.8 (25‐437)/27 |
Leukocytes (103/μL) |
12.4 (5.2‐32.0)/27 |
Creatinine (mg/dL) |
3.7 (0.63‐16.3)/27 |